Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

by Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, Jaime D. Blais
Published 2017-11-01

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial

by Maria V. Irazabal, Jaime D. Blais, Ronald D. Perrone, Ron T. Gansevoort, Arlene B. Chapman, Olivier Devuyst, Eiji Higashihara, Peter C. Harris, Wen Zhou, John Ouyang, Frank S. Czerwiec, Vicente E. Torres
Published 2016-11-01